The effects of oxygen-ozone therapy on regulatory T-cell responses in multiple sclerosis patients
Tahmasebi S, Qasim MT, Krivenkova MV, et al. Cell Biology International, 2021.
- Study type
- Cohort study
- People studied
- 20 people
- Population
- Relapsing-remitting multiple sclerosis patients
- Published
- 2021, Cell Biology International
- Identifiers
- PMID 33724614, DOI 10.1002/cbin.11589
What the authors reported
In 20 relapsing-remitting MS patients treated with ozone autohemotherapy twice weekly for 6 months, regulatory T-cell frequency and related anti-inflammatory markers (FoxP3, IL-10, TGF-beta) rose after treatment compared with before.
What limits this result
Single-arm before-after design with no untreated control group and no blinding; measures a laboratory immune marker, not a clinical disability or symptom outcome.
How ozone acts on blood and cells, how blood filters work, and studies that measure markers in the blood rather than how patients fare. None of these shows whether EBO2 helps patients. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Autoimmune Conditions: Rheumatoid Arthritis, MS, Lupus and the Evidence
What the ACR rheumatoid arthritis guideline and small ozone autohemotherapy studies actually show about EBO2 (also called EBOO) for autoimmune disease.